Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

A graphical representation of the study conducted here to find potential phyto-compounds inhibiting West Nile Virus envelope glycoprotein.

More »

Fig 1 Expand

Fig 2.

(Ⅰ) The WNV envelope glycoprotein’s (PDB ID: 2HG0) structure, comprising co-crystallized ligands, side chains, water molecules, and hetatm molecules, (Ⅱ) E-glycoprotein’s structure (Chain-A); applying the removal of water molecules, hetatm molecules, and co-crystallized ligands.

More »

Fig 2 Expand

Table 1.

Compounds identification according to PubChem CID, name, and docking value of the top three compounds, as well as Favipiravir (control), with therapeutic uses.

More »

Table 1 Expand

Table 2.

Highlighting the amino acid residues associated with H-bonds, polar bonds, and hydrophobic bonds that form between the target protein and selected three compounds, as well as the control.

More »

Table 2 Expand

Fig 3.

The relationship between the WNV’s E glycoprotein (2HG0) and selected three compounds in 3D and 2D formats, with compounds (A) CID: 359, (B) CID: 9064, (C) CID: 25310, and (D) CID: 492405 in the protein’s active pocket.

More »

Fig 3 Expand

Fig 4.

The bar diagram shows MM-GBSA of the compounds CID: 359, 9064, 25310, and the control 492405 demonstrating negative binding free energies.

More »

Fig 4 Expand

Table 3.

List of Pk characteristics of three lead compounds with the control (Favipiravir).

More »

Table 3 Expand

Table 4.

List of toxicity characteristics of three lead compounds with the control (Favipiravir).

More »

Table 4 Expand

Fig 5.

The apoprotein’s RMSD, RMSF, Rg, and SASA values are displayed complexed with the three lead compounds and control chosen and extracted from 100 ns MD trajectory complex system’s C

α atoms.

More »

Fig 5 Expand

Fig 6.

The bar charts display the P-L interactions determined during the 100 ns simulation period.

In this figure, the 2HG0 protein of the WNV shows interaction with CID: 359 (A), 9064 (B), 25310 (C), and 492405 (control) (D).

More »

Fig 6 Expand

Fig 7.

The interaction profiles between the ligand and the apoprotein are presented using the ligand-apoprotein detailed schematic diagram where CID: 359 (A), 9064 (B), 25310 (C), and 492405 (control) (D) illustrate the conformational isomerism of the ligands binding to wild type protein.

More »

Fig 7 Expand

Fig 8.

Reflecting the number of H-bonds established by the four selected compounds with the target macromolecule during the 100 ns MD simulation period.

The ordinate of the Y-axis represents the number of hydrogen bonds in the P-L complex, while the ordinate of the X-axis represents time in ns. The colors orange, grey, yellow, and red symbolize CID: 359, 9064, 25310, and 492405 (control), correspondingly.

More »

Fig 8 Expand

Fig 9.

Eigenvalue versus proportion of variance in Principal Component Analysis, depicted across three unique panels representing different areas.

Here, (A) CID: 25310, (B) CID: 9064, (C) CID: 359, (D) CID: 492405 (control), and (E) Apoprotein (2HG0) are referenced.

More »

Fig 9 Expand

Fig 10.

A comprehensive dynamic cross-correlation map where black indicates positive residue correlations and sea green denotes negative residue correlations.

In this context, (A) CID: 359, (B) CID: 9064, (C) CID: 25310, (D) CID: 492405 (control), and (E) Apoprotein (2HG0) are referenced.

More »

Fig 10 Expand

More »

Expand